5298results about "Pharmaceutical non-active ingredients" patented technology

The present disclosure provides daptomycin formulations which have improved chemical stability, faster reconstitution times when reconstituted from the solid state and longer in-use stability. The compositions comprise daptomycin, one basic amino acid or its salt and optionally one or more pH adjusting agents.

The invention relates to a pharmaceutical composition comprising or essentially consisting of - a core; - an active ingredient coating layer comprising Duloxetine or a physiologically acceptable salt thereof, preferably Duloxetine hydrochloride; - an intermediate coating layer; - optionally, an enteric coating layer; and - optionally, a finishing coating layer; wherein the active ingredient coating layer and the intermediate coating layer comprises a nitrite scavenger, preferably ascorbic acid.

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The application belongs to the technical field of medicine, and particularly discloses a nilotinib composition and application thereof.The nilotinib composition in the technical scheme has good stability and resuspension in a long-term storage process through the addition of a suspending agent and a filler, improves the safety of drug use of patients, and ensures the quality uniformity of the drug.The nilotinib composition in the technical scheme can be directly taken after being suspended with water, obviously improves the convenience of drug administration for the dysphagia population and children compared to the existing capsule preparation, improves the acceptability of the preparation, is convenient for dose segmentation, reduces the problem that the drug use of patients cannot cover the usage and dosage calculated according to the body surface area, and has higher patient compliance compared to the capsule.

The present invention relates to a combination of (i) an anti-Fibroblast Activating Protein α (FAP) antibody-cytolysin conjugate having the formula A-(L-D)p or a pharmaceutically acceptable salt or solvate thereof and (ii) an immune checkpoint inhibitor (ICI) for use in a method of treating metastatic cancer in a mammalian subject, wherein A is an anti-FAP antibody that selectively binds FAP, L is a linker, D is a drug comprising a cytolysin and p is 1 to 10, wherein the method comprises simultaneous, sequential or separate administration of the antibody-cytolysin conjugate or the pharmaceutically acceptable salt or solvate thereof and the ICI to the subject, wherein the metastatic cancer comprises a primary cancer and metastasis.

The present invention relates to a composition of aliphatic emulsion preparation for malignant thoracicoabdominal hydrops and its preparation method. It is made up by adopting pure natural anticancer medicine elemene and at least one polysaccharide selected from ginseng polysaccharide, astragalus polysaccharide, acanthopanax polysaccharide and lyceum polysaccharide as raw material. Said invention can obviously raise solubility of medicine, increase stability of medicine, effectively remove and kill cancer cells and raise immunity of body.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application provides a lipoic acid doped lipid nanoparticle and a preparation method and application thereof, and belongs to the technical field of biological medicines.The lipoic acid doped lipid nanoparticle provided by the application is composed of nucleic acid drugs and a lipid composition, and the lipid composition is composed of ionizable lipids, sterols, PEGylated lipids, auxiliary lipids and lipoic acid.The application has the beneficial effect that the nucleic acid drug delivery effect of the traditional four-component lipid nanoparticle can be enhanced by introducing lipoic acid, and high-efficiency nucleic acid drug transfection can be achieved without causing obvious cytotoxicity, and the biological safety is high.

The application relates to a use of a traditional Chinese medicine composition in preparation of a medicine for inhibiting human papilloma virus, which is prepared from raw medicine with the following weight parts: 70-100 parts of rhubarb, 70-100 parts of mirabilite, 70-100 parts of gallnut. The traditional Chinese medicine composition has excellent killing effect on human papilloma virus (HPV), low cost, small toxic and side effects, and has a good application prospect.

The present application relates to a kind of robecoxib liposome and its preparation method and application, the preparation raw material of the robecoxib liposome includes phospholipid, cholesterol and robecoxib, and the robecoxib is encapsulated in lipid bilayer, and the robecoxib liposome of the present application improves the solubility of robecoxib, and has higher encapsulation efficiency and drug loading.

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

The application discloses a kind of by polydopamine mesoporous nanoparticles crosslinked sulfhydrylated hyaluronic acid hydrogel and its preparation method and application, with dopamine and 4-formylphenylboronic acid as monomer, with trimethylbenzene as and poloxamer as template agent, in weak alkaline (pH=8.4), oxygen exists in the environment, by the oxidation self-polymerization reaction between monomer Preparation of polydopamine nanoparticles with mesoporous structure.Then the water dispersion of polydopamine nanoparticles is mixed with sulfhydrylated hyaluronic acid solution according to certain proportion, and the hydrogel dressing with injectable property is prepared.The hydrogel is expected to be used as skin wound dressing for the treatment of diabetic wounds.

The present disclosure provides LNPs comprising payload molecules, eg, mRNA therapeutics, for the treatment of diseases or disorders that would benefit from delivery of the payload molecule to airway cells.

Multifunctional nanoparticles incorporate an ERS inducer (p97 inhibitors) and immunotherapeutics (immune-modulating miR or aptamer plus immunoadjuvants) to address the poor aqueous solubility and toxicity associated with p97 inhibitors and immunotherapeutics while also enhancing the immune activation of these therapeutics. The nanoformulation offers several advantages, such as pH-sensitivity, self-detachable coating, active targeting, and intracellular localization in tumors, and has the potential to overcome the limitations of systemic administration, such as the degradation of nucleic acid therapeutics and toxicities associated with ERS inducer.

Described herein are anti-NaPi2b antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analog of Formula (I). The antibody construct of the ADC comprises an amino acid modification in the Fc that knocks out binding to Fc gamma receptors. The ADCs are useful as therapeutic agents, among others, in the treatment of cancer.

The present disclosure provides a HER2 binder comprising a VHH domain that specifically binds to HER2. Also provided are nucleic acids encoding the protein, vectors and host cells comprising the nucleic acids, and methods of manufacturing and using the HER2 binder. The present disclosure also provides a HER2 binder conjugate in which the protein is conjugated to a detectable label, and a HER2-binding targeted radiotherapy agent for therapeutic and / or diagnostic purposes. Also provided are methods of using the HER2 binder for detecting, monitoring and / or treating diseases and conditions such as cancer.

The present disclosure provides compounds of Formula (I) (e.g., Formula (I-1), Formula (Ia) (e.g., Formulas (Ia-1), (Ia-2), (Ia-3), (Ia-4), (Ia-5), or (Ia-6)), or Formula (Ib) (e.g., Formula (Ib-1) or (Ib-2)) or pharmaceutically acceptable salts thereof, which induce degradation of BCL6 protein. These compounds are useful, for example, for treating cancer in a subject (e.g., a human). The present disclosure also provides compositions containing the compounds and methods of using and preparing them.

The application discloses a novel fullerene hydrogel and a preparation method and application thereof. The fullerene hydrogel is formed by chemical cross-linking of a fullerene derivative shown in formula I and oxidized hyaluronic acid (oxHA). The fullerene-hyaluronic acid hydrogel material provided by the application has a porous framework, a large pore size and a cell loading potential.

The application provides a preparation method of NK cell-derived nanovesicles and application thereof. Specifically, the application provides NK cell-derived nanovesicles (NK-NVs) which are similar to the characteristics and functions of NK cell-derived extracellular vesicles by an extrusion method / stress gradient membrane remodeling technology, and also provides a drug composition, a drug delivery system and corresponding use of the NK-NVs as a delivery carrier for delivering an antitumor drug. The preparation method of the application can mass-produce NK-NVs and kill various types of tumor cells. The NK-NVs have multiple advantages in drug delivery, so that they are expected to be a new choice for tumor immunotherapy, especially for tumor cells with drug resistance, and can significantly improve the sensitivity to chemotherapeutic drugs, and have a wide application prospect.

The application belongs to the technical field of biological medicine, and discloses an in-situ vaccine type mRNA-tLNP preparation for solid tumor treatment and preparation and application thereof. The preparation is designed by double targets, so that CAR-T kills more tumor cells to overcome tumor heterogeneity, changes the tumor immune microenvironment through autocrine fusion proteins (anti-PD-1 scFv and TGFbetaRII, IL-15 and Flt3L, CD40L), promotes T cell proliferation, and recruits and activates dendritic cells, cross-presents new antigens in the tumor local part, and produces in-situ vaccination effects; circular RNA encoding the above proteins is prepared, and the circular RNA is wrapped by lipid nanoparticles modified by CD3 antibodies, so as to be directly delivered to the body, and a significant solid tumor treatment effect is produced.

Compositions and methods are provided that include binding partners that specifically bind to peptide conjugate / MHC complexes, including peptide conjugates formed by covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies and antibody derivatives that specifically bind to the peptide conjugate / MHC complex.

This application provides an insulin analogue and its use, the insulin analogue comprising an A chain and a B chain; the sequence of the A chain includes: GIVEQCCTSICSLX aa14 QLENYCN, the B-chain sequence contains: FVNQHLCGSHLVEALY aa16 LVCGEY aa22 GF Y aa25 YTPY aa29 Y aa30 ; where X aa14 Selected from E, Y, K, or D, Y aa16 Selected from Y or H, Y aa22 Selected from Q, S, T, Y, or N, Y aa25 Selected from F, H, or K, Y aa29 Let R and Y be... aa30 It does not exist; the condition is: X aa14 and Y aa25 There is only one K in the insulin analogue. The insulin derivative obtained by the above-mentioned insulin analogue has significantly better in vitro INSR phosphorylation activity and glucose uptake activity than the control drug Icodec. The efficacy (PD) was evaluated using a type 1 diabetic rat model. It has the potential to be administered once a week or less frequently and has a significant hypoglycemic effect.

To provide an effective antibody-drug conjugate comprising an anti-FRα antibody, with high specificity, low toxicity (improved therapeutic index) and differentiated mechanism of action of the payload.SOLUTION: Provided is an antibody-drug conjugate in which the antibody specifically binds to folate receptor alpha (FRα) and in which the drug is selected from topoisomerase I inhibitors, camptothecin analogs such as exatecan. Such an antibody-drug conjugate is especially useful for treating proliferative diseases including cancers such as ovarian, breast or lung cancer.SELECTED DRAWING: None

This invention provides an anti-VMAT2 antibody or its antigen-binding fragment, compositions thereof, and applications. Specifically, it provides an anti-VMAT2 antibody or its antigen-binding fragment that can effectively bind to the intracellular region of the human VMAT2 protein. This invention also provides antibody-drug conjugates containing this antibody or antigen-binding fragment, which can be used to prepare drugs for treating diseases overexpressing VMAT2 and have promising application prospects.

The present invention relates to a temperature-responsive in situ gelling composition comprising an amphiphilic triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO), a water-soluble hydrophilic polymer, wherein the composition further comprises at least one lipid agent. The lipid agent is selected from the group consisting of a phospholipid, a sterol, a glyceride, a fatty acid or ester and derivative, a fatty alcohol, a cholesterol and derivative or a combination of more than one lipid agent. The present invention further relates to a vascular embolization agent comprising the temperature-responsive in situ gelling composition.

Polymeric ocular inserts are provided that can be dissolvable when placed in the fornix of the eye. These inserts can comprise one or more polymers and a softening agent / plasticizer such that when inserted into the eye, the polymers and softening agent / plasticizer can absorb tears, dissolve, and slowly release a lubricant into the tear film to lubricate and protect the ocular surface for a prolonged duration. Increasing the residence time on the ocular surface to achieve more sustained relief can decrease the frequency of dosing and the patient burden typically associated with topical drop usage. These polymeric ocular inserts can also comprise one or more pharmaceutically active agents.

Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked to the oligonucleotide via a linker that target a human dystrophin gene, compositions including the same, and methods of use thereof.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising: a) immediate-release granules comprising i. an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and ii. a filler; and b) sustained-release pellets comprising: i. a pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and (2) a filler; and ii. on the pellet core iii. A sustained-release pellet comprising a subcoat provided on the subcoat, the content of which is 10 to 20% by weight based on the weight of the pellet core and contains a film-forming agent, and iii. a sustained-release coating provided on the subcoat, the content of which is 25 to 100% by weight based on the weight of the pellet core coated with the subcoat and contains a film-forming agent, wherein the amount of active ingredient in the immediate-release granules accounts for 70 to 80% by weight of the total weight of active ingredients in the pharmaceutical composition, and the amount of active ingredient in the sustained-release pellets accounts for 20 to 30% by weight of the total weight of active ingredients in the pharmaceutical composition. In yet another aspect, the present invention relates to a method for producing a pharmaceutical composition and a pharmaceutical composition for use in a method of pretreatment of cancer.

The present application provides a kind of probiotic compound and its application in preventing and repairing gynecological reproductive tract mucosa damage.The compound is composed of core probiotic, mucosa repair auxiliary component and sustained-release carrier, which are collectively encapsulated in the sustained-release carrier to form drug-loaded microspheres, with total viable count ≥1×10 10 CFU / g; the mucosa repair auxiliary component is a specific ratio combination of snail mucus active peptide, L-arginine and phytosterol; the sustained-release carrier is γ-ray modified chitosan and sodium alginate composite microspheres, which are matched with prebiotics for directional synergism, realize bacteriostasis, mucosa repair and microecological regulation functions through multi-component synergy, solve the problem of easy inactivation and weak repair ability of traditional products, provide a safe and effective new solution for gynecological health, and can be prepared into various dosage forms such as suppositories and gels, with wide application prospect.